For many patients with myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes (MDS), their disease will be chronic, giving them a long-term cancer experience, said Jennifer Vaughn, MD, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital.
With most patients with myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes (MDS) experiencing long-term, chronic disease, it’s important to discuss their priorities and set up the relationship with their providers upfront, explained Jennifer Vaughn, MD, assistant professor in the division of hematology at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute.
Transcript
What do you wish more patients with myeloproliferative neoplasms and myelodysplastic syndromes were aware of as they are being treated?
I wish that all cancer patients understood their role in helping define the true meaning of value-based care. I think that their opinions are really about what their priorities are in terms of their cancer experience are the aspects that should be shaping how we mold value-based care and are planning for it as we move to those sorts of models in health care.
In terms of, specifically, myelodysplastic syndromes and myeloproliferative disorders, they are part of an ever-growing catchment of cancer patients that have more chronic disease or at least a subset of them have actually more chronic disease, and so they’re going to have a more long-term cancer experience. So, their relationship with their providers and with the health care system, is going to be extended for many years if not decades.
And so, I think realizing upfront, this is going to be a long-term commitment and a long-term relationship, speaking at the beginning: how do they define what they find valuable in their treatment experience. And what are going to be their priorities as they continue to get care, whether that be increased longevity, increased quality of life, thinking about their financial well-being and avoid the financial toxicity, or participation in research that helps them to feel like they're contributing to the development of new therapies as a whole.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Congress Urged to Repeal Comstock Act Threatening Reproductive Rights and Public Health
May 16th 2024In a joint letter addressed to Congress, Healthcare Across Borders, Take Back the Court Action Fund, and UltraViolet Action called out the resurgence of the Comstock Act, urging immediate action to repeal this century-old law that threatens reproductive rights and public health in the US.
Read More
Atypical Marker Expression in T-Cell Acute Lymphoblastic Leukemia/Lymphoma
May 15th 2024Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without typical immaturity markers but with rare γδ T-cell receptor expression.
Read More